Cargando…
Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013
BACKGROUND: Tumor testing for mutations in the epidermal growth factor receptor (EGFR) gene is indicated for all newly diagnosed, metastatic lung cancer patients, who may be candidates for first-line treatment with an EGFR tyrosine kinase inhibitor. Few studies have analyzed population-level testing...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859516/ https://www.ncbi.nlm.nih.gov/pubmed/29554880 http://dx.doi.org/10.1186/s12885-018-4190-3 |